Inflection Biosciences recognises the importance of effective strategic partnering across the drug development process in the successful achievement of its business objectives. Partnering is central to the key activities of the company, with research and academic alliance partners providing Inflection Biosciences with access to promising cancer discoveries, contract research organisations underpinning its capital efficient drug development objectives and large pharmaceutical company partners playing a prominent role in the execution of the later stage clinical development phases followed by launch of products in the market place. 

To support the development of AUM302 (formerly IBL-302) the company has collaborated with AUM Biosciences Ltd in Singapore, with AUM Biosciences now responsible for the further development of that program.

The company has also established an international network of research partners to support the development of its programs. The company believes that the research data being achieved through this network will be important in informing its clinical development priorities. Collaboration partnerships which have been announced to date include:

  • Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid
  • The University of Texas M. D. Anderson Cancer Center
  • Trinity College Dublin, Ireland
  • National University of Ireland, Galway
  • Royal College of Surgeons in Ireland
  • Thomas Jefferson University, Philadelphia
  • North Carolina Central University
  • Royal North Shore Hospital, New South Wales, Australia
  • Munich Klinikum der Universität München, Germany
  • Lund University Cancer Centre, Sweden



Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2020 Inflection Biosciences.   Web Design by Webtrade